During a follow-up of approximately 2.5 years, we observed differences in the overall gout incidence: 20.26 per 1000 patient-years for SGLT2 inhibitor users and 24.30 per 1000 patient-years for DPP4 inhibitor users. The gene discussed is SLC5A2; the disease is gout.